Arrow Ventures Initiates $125 Million Fund Dedicated to Next-Gen Animal Health Therapeutics

NEW YORK, N.Y. — October 9, 2026 — Specialized venture capital firm Arrow Ventures has launched fundraising for a targeted $125 million investment vehicle dedicated exclusively to animal health biotechnology, novel therapeutics, and companion animal digital health platforms across North America. The fund aims to bridge the early-stage financing gap for early clinical-stage veterinary startups transitioning discoveries from human biopharma to animal health applications.

Strategic Allocation & Investment Focus

The $125 million fund will deploy capital across three core pillars within the expanding animal health ecosystem:

• Biotech & Novel Therapeutics: Funding advanced monoclonal antibodies, targeted small molecules, and gene therapies addressing canine/feline oncology, chronic kidney disease, and osteoarthritis.

• Livestock Biosecurity Tech: Supporting early-stage startups developing rapid diagnostics, vaccine vectors, and precision health tracking for swine, poultry, and dairy production.

• Digital Health Platforms: Scaling enterprise software solutions that improve veterinary practice efficiency, client retention, and remote patient monitoring.

Industry Outlook & Capital Deployment

As institutional investors increasingly recognize the resilience of the companion animal sector and the demand for biosecure food production, Arrow Ventures expects to complete initial closings in early 2027, accelerating commercial growth for high-impact veterinary health innovations.